CO4970769A1 - Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones - Google Patents

Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones

Info

Publication number
CO4970769A1
CO4970769A1 CO98061475A CO98061475A CO4970769A1 CO 4970769 A1 CO4970769 A1 CO 4970769A1 CO 98061475 A CO98061475 A CO 98061475A CO 98061475 A CO98061475 A CO 98061475A CO 4970769 A1 CO4970769 A1 CO 4970769A1
Authority
CO
Colombia
Prior art keywords
insulin
compositions
derivatized
glucose
blood
Prior art date
Application number
CO98061475A
Other languages
English (en)
Inventor
Mark Laurence Brader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4970769A1 publication Critical patent/CO4970769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición insoluble que comprende: a) una proteína derivatizada seleccionada del grupo formado por insulina derivatizada, análogos de insulina derivatizada y proinsulinas derivatizadas, b) un compuesto complejante, c) un compuesto estabilizador de hexámeros y d) un catión metálico divalente. 2Un procedimiento para preparar la composición insoluble de acuerdo con la reivindicación 1, que comprende: a) disolver una proteína derivatizada, un compuesto estabilizador de hexámeros y un catión metálico divalente en un disolvente acuoso que tiene un pH que permite la formación de hexámeros de la proteína derivatizada y b) añadir un compuesto complejante.
CO98061475A 1997-10-24 1998-10-22 Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones CO4970769A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6310497P 1997-10-24 1997-10-24
US8893098P 1998-06-11 1998-06-11

Publications (1)

Publication Number Publication Date
CO4970769A1 true CO4970769A1 (es) 2000-11-07

Family

ID=26743043

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98061475A CO4970769A1 (es) 1997-10-24 1998-10-22 Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones

Country Status (21)

Country Link
US (3) US6268335B1 (es)
EP (1) EP1039920A4 (es)
JP (2) JP2001521006A (es)
KR (1) KR20010024556A (es)
CN (1) CN1276731A (es)
AR (1) AR020047A1 (es)
AU (2) AU1111799A (es)
BR (1) BR9813111A (es)
CA (2) CA2306905A1 (es)
CO (1) CO4970769A1 (es)
EA (1) EA200000453A1 (es)
HR (1) HRP20000236A2 (es)
HU (1) HUP0004169A3 (es)
ID (1) ID24890A (es)
IL (1) IL134901A0 (es)
NO (1) NO20002038L (es)
PE (1) PE123799A1 (es)
PL (1) PL340255A1 (es)
SV (1) SV1998000125A (es)
TR (1) TR200001050T2 (es)
WO (2) WO1999021573A1 (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020155614A1 (en) * 2001-02-21 2002-10-24 Tomlinson Andrew J. Peptide esterification
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
DE60217367T2 (de) * 2001-09-19 2007-10-18 Elan Pharma International Ltd. Nanopartikelzusammensetzungen enthaltend insulin
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
KR20040070237A (ko) * 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 연장된 작용 시간을 갖는 인슐린 분자
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
JP2006519791A (ja) * 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
ES2328579T3 (es) * 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
ATE517119T1 (de) * 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
EP1863840A1 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2023947A4 (en) * 2006-05-10 2009-11-25 Smithkline Beecham Corp COMPOSITION AND METHOD IMPROVING THE CELL PERMEABILITY OF A COMPOUND
WO2007135118A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
EP2074140B8 (en) * 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CN102065885A (zh) * 2008-04-22 2011-05-18 卡斯西部储备大学 同种型特异性的胰岛素类似物
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
US9050370B2 (en) 2009-01-28 2015-06-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
US20100198188A1 (en) * 2009-02-05 2010-08-05 Abbott Diabetes Care Inc. Devices and Methods for Metering Insoluble Active Agent Particles
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US20120241356A1 (en) * 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
US20120232002A1 (en) * 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
BR112012014025A2 (pt) 2009-12-11 2017-01-31 Univ Case Western Reserve análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira e método de tratar um paciente
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
DK2983697T3 (en) 2013-04-03 2019-02-25 Sanofi Sa TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en) * 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CA2957714A1 (en) * 2014-08-11 2016-02-18 Albany Medical College Myristoylated leptin-related peptides and uses thereof
US10392429B2 (en) 2014-10-06 2019-08-27 Case Western Reserve University Biphasic single-chain insulin analogues
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3341403B1 (en) * 2015-08-25 2022-01-05 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
US11230585B2 (en) 2016-09-06 2022-01-25 Chemical & Biopharmaceutical Laboratories Of Patra Proinsulin derivatives
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
EP3548058B1 (en) 2016-12-05 2022-06-22 Nuritas Limited Compositions comprising peptide wkdeagkplvk
CN110087674B (zh) 2016-12-16 2023-01-03 诺和诺德股份有限公司 含胰岛素的药物组合物
US20200147215A1 (en) * 2017-04-24 2020-05-14 Simon H. Friedman Drug conjugates with photocleavable solubility modulators
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
CN112512534A (zh) * 2018-05-14 2021-03-16 艾伊拉米治疗有限公司 用于回溶为高浓度液态溶液的胰岛素制剂
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
MX2021006972A (es) 2018-12-11 2021-08-16 Sanofi Sa Conjugados de insulina.
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
TWI773009B (zh) 2019-12-11 2022-08-01 丹麥商諾佛 儂迪克股份有限公司 新穎之胰島素類似物及其用途
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
JP7456007B2 (ja) 2020-05-15 2024-03-26 イーライ リリー アンド カンパニー 長時間作用アシル化インスリン化合物
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2022125587A1 (en) * 2020-12-07 2022-06-16 Case Western Reserve University Acylated single-chain insulin analogues
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3865325A (en) 1971-07-02 1975-02-11 Dylaker Computer Systems Inc Flexible tape reel
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
JPS58501455A (ja) 1981-09-15 1983-09-01 ノルデイスク　インシユリンラボラトリユ−ム 人インシユリンまたはそのｂ−３０エステルの製造法
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
WO1990001038A1 (en) 1988-07-20 1990-02-08 Nordisk Gentofte A/S Human insulin analogs and preparations containing them
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE122006000017I1 (de) 1993-06-21 2006-06-29 Novo Nordisk As ASP-B28-Insulinkristalle
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CN1196061A (zh) 1995-03-17 1998-10-14 诺沃挪第克公司 胰岛素衍生物
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
ATE369146T1 (de) 1996-06-20 2007-08-15 Novo Nordisk As Insulinpreparation mit mannitol
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
ES2242270T3 (es) 1997-02-07 2005-11-01 Novo Nordisk A/S Cristalizacion de proteinas.
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.

Also Published As

Publication number Publication date
HRP20000236A2 (en) 2001-02-28
ID24890A (id) 2000-08-31
PE123799A1 (es) 1999-12-13
US20020082199A1 (en) 2002-06-27
JP2001521006A (ja) 2001-11-06
PL340255A1 (en) 2001-01-29
AU747926B2 (en) 2002-05-30
WO1999021578A1 (en) 1999-05-06
BR9813111A (pt) 2000-08-15
AR020047A1 (es) 2002-04-10
CN1276731A (zh) 2000-12-13
AU1116699A (en) 1999-05-17
HUP0004169A2 (hu) 2001-05-28
JP2001521004A (ja) 2001-11-06
US20010036916A1 (en) 2001-11-01
EA200000453A1 (ru) 2000-10-30
KR20010024556A (ko) 2001-03-26
AU1111799A (en) 1999-05-17
EP1039920A4 (en) 2003-05-28
CA2306905A1 (en) 1999-05-06
US6465426B2 (en) 2002-10-15
NO20002038L (no) 2000-06-26
WO1999021573A1 (en) 1999-05-06
NO20002038D0 (no) 2000-04-18
IL134901A0 (en) 2001-05-20
SV1998000125A (es) 1999-05-24
HUP0004169A3 (en) 2001-06-28
TR200001050T2 (tr) 2000-08-21
CA2306877A1 (en) 1999-05-06
EP1039920A1 (en) 2000-10-04
US6268335B1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
CO4970769A1 (es) Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones
ATE97918T1 (de) Antikoagulierendes protein.
BR0014767A (pt) Fibras de sementes de plantas e uso
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
DE68903846D1 (de) Neue galenische form von fenofibrat.
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
FI884051A (fi) Menetelmä stabiloitujen humaaniproteiinivalmisteiden valmistamiseksi
SE8803570D0 (sv) 4h-1-bensopyran-4-on-derivat eller dess salt, foerfarande foer framstaellning daerav samt farmaceutisk komposition innehaallande detsamma som aktiv komponent
JPS6440433A (en) Aqueous liquid composition of thrombin
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
DE59308415D1 (de) Stabile lyophilisierte pharmazeutische zubereitungen von g-csf
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
DE69401204D1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DK1268498T3 (da) Kardioprotektive phosphater
HUT58813A (en) Process for producing tissue-plasminogen activator derivative
AU5007196A (en) Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation process and pharmaceutical compositions comprising them
ATE124869T1 (de) Stabilisierung von calcitonin enthaltenden pharmazeutischen verbindungen.
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
CA2020663A1 (en) Substitution analogues of magainin peptides
PT91302A (pt) Processo para a preparacao de composicoes farmaceuticas contendo imidazo {2,1-a} isoquinolinas substituidas por 5-heteroarilo ou 5-arilo
DE69923426D1 (de) Verfahren zur herstellung von isoflavonen
YU136390A (sh) Postupak za dobijanje supstituisanih 2-imidazolina
AU557365B2 (en) Liquid residue reducing preparations containing octane-1 phosphonic acid
ES2038663T3 (es) Un metodo para preparar una composicion para la aplicacion por via topica, destinada al tratamiento de la enfermedad epitelial hiperproliferativa.